The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Treatment options for pregnant patients with non-small cell lung cancer
Martina Imbimbo, MD, Ente Ospedaliero Cantonale, Lugano, Switzerland, provides an overview on treatment strategies for pregnant patients with non-small cell lung cancer (NSCLC). Chemotherapy can be considered particularly in the second and third trimesters, as a potentially safer alternative to the first trimester. While data on chemotherapy and tyrosine kinase inhibitors (TKIs) in pregnancy is limited, some reassuring data suggest that chemotherapy may be a viable option in certain cases. However, monitoring both the mother and the child is essential to assess potential impact of TKIs. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah so for chemotherapy we know that we can do it so from second and third trimester and that is always a good option so if you if you need to give chemo for TKIs we don’t have many data but as I show in my presentation there are some reassuring data with some TKIs then you know 11 cases do not make a clinical trial. So most of the time if you can spare the first trimester this is better so maybe give it in the last two thirds, second and third trimester and then it’s very important to have a very good gynecological follow-up so to really follow the mother and the child because the other risk is also that the mother could have less effect of the TKI on her disease which we are not really seeing but these are very special patients and you need to follow them very closely...
Yeah so for chemotherapy we know that we can do it so from second and third trimester and that is always a good option so if you if you need to give chemo for TKIs we don’t have many data but as I show in my presentation there are some reassuring data with some TKIs then you know 11 cases do not make a clinical trial. So most of the time if you can spare the first trimester this is better so maybe give it in the last two thirds, second and third trimester and then it’s very important to have a very good gynecological follow-up so to really follow the mother and the child because the other risk is also that the mother could have less effect of the TKI on her disease which we are not really seeing but these are very special patients and you need to follow them very closely.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
